NCT06290557View on ClinicalTrials.gov

First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy ofHY-133

PHASE1RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2026

Conditions
Staphylococcus Aureus
Interventions
DRUG

HY_133

A recombinant chimeric bacteriophage endolysin HY-133

DRUG

Placebo

Placebo

Trial Locations (2)

D-72075

RECRUITING

Department of Dermatology, University Hospital Tuebingen, Tübingen

Unknown

RECRUITING

Department of Dermatology, Tübingen

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER